Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilbert J Cote

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
The Journal of Clinical Endocrinology and Metabolism|December 31, 2010
Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicatorsMontserrat Ayala-Ramirez, Lei Feng, Marcella M Johnson, et al.
The Journal of Clinical Investigation|December 19, 2002
Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin geneAna O Hoff, Philip Catala-Lehnen, Pamela M Thomas, et al.
The Journal of Clinical Endocrinology and Metabolism|July 9, 2004
A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinomaCamilo Jimenez, Gerald T Dang, Pamela N Schultz, et al.
The Journal of Biological Chemistry|March 22, 2015
A novel dual kinase function of the RET proto-oncogene negatively regulates activating transcription factor 4-mediated apoptosisRozita Bagheri-Yarmand, Krishna M Sinha, Anupama E Gururaj, et al.
Thyroid : Official Journal of the American Thyroid Association|March 13, 2014
Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutationsThereasa A Rich, Lei Feng, Naifa Busaidy, et al.
Oncotarget|April 23, 2015
Differential expression of cell cycle regulators in CDK5-dependent medullary thyroid carcinoma tumorigenesisKarine Pozo, Antje Hillmann, Alexander Augustyn, et al.
Surgery|October 26, 2019
Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinomaJessica E Maxwell, Maria K Gule-Monroe, Vivek Subbiah, et al.
International Journal of Surgery (London, England)|May 24, 2016
Parathyroid carcinoma and atypical parathyroid neoplasms in MEN1 patients; A clinico-pathologic challenge. The MD Anderson case series and review of the literatureIoannis Christakis, Naifa L Busaidy, Gilbert J Cote, et al.
The Journal of Clinical Endocrinology and Metabolism|June 15, 2017
Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease AggressivenessRachel K Voss, Lei Feng, Jeffrey E Lee, et al.
The Journal of Clinical Endocrinology and Metabolism|March 18, 2014
Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenibRamona Dadu, Catherine Devine, Mike Hernandez, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
The Journal of Clinical Endocrinology and Metabolism|December 31, 2010
Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicatorsMontserrat Ayala-Ramirez, Lei Feng, Marcella M Johnson, et al.
The Journal of Clinical Investigation|December 19, 2002
Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin geneAna O Hoff, Philip Catala-Lehnen, Pamela M Thomas, et al.
The Journal of Clinical Endocrinology and Metabolism|July 9, 2004
A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinomaCamilo Jimenez, Gerald T Dang, Pamela N Schultz, et al.
The Journal of Biological Chemistry|March 22, 2015
A novel dual kinase function of the RET proto-oncogene negatively regulates activating transcription factor 4-mediated apoptosisRozita Bagheri-Yarmand, Krishna M Sinha, Anupama E Gururaj, et al.
Thyroid : Official Journal of the American Thyroid Association|March 13, 2014
Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutationsThereasa A Rich, Lei Feng, Naifa Busaidy, et al.
Oncotarget|April 23, 2015
Differential expression of cell cycle regulators in CDK5-dependent medullary thyroid carcinoma tumorigenesisKarine Pozo, Antje Hillmann, Alexander Augustyn, et al.
Surgery|October 26, 2019
Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinomaJessica E Maxwell, Maria K Gule-Monroe, Vivek Subbiah, et al.
International Journal of Surgery (London, England)|May 24, 2016
Parathyroid carcinoma and atypical parathyroid neoplasms in MEN1 patients; A clinico-pathologic challenge. The MD Anderson case series and review of the literatureIoannis Christakis, Naifa L Busaidy, Gilbert J Cote, et al.
The Journal of Clinical Endocrinology and Metabolism|June 15, 2017
Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease AggressivenessRachel K Voss, Lei Feng, Jeffrey E Lee, et al.
The Journal of Clinical Endocrinology and Metabolism|March 18, 2014
Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenibRamona Dadu, Catherine Devine, Mike Hernandez, et al.
Pageof 7